FGF21 and metabolic dysfunction-associated steatotic liver disease: Thus, FGF21 may represent a novel therapeutic molecule based on the findings that it protects animals from diet-induced obesity and reduces hepatic lipid accumulation, enhances glucose metabolism, and thus prevents hepatic steatosis, fibrosis, and NAFLD when administered to diabetic rodents17,18.